Circassia Pharmaceuticals is set to exercise an option to purchase full US commercial rights of chronic obstructive pulmonary disease treatment, Tudorza (aclidinium), from AstraZeneca.
12 Dec 2018
07 Dec 2018
AstraZeneca has completed its $350m sale of its rights to asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Switzerland-based Covis Pharma.
06 Dec 2018
Tris Pharma has voluntarily recalled three lots of Infants' Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level in the US.
03 Dec 2018
Crown Laboratories, a privately held, fully integrated global skin care company, has acquired North American distribution rights of five OTC consumer brands from GlaxoSmithKline (GSK).
23 Nov 2018
British drugmaker GlaxoSmithKline (GSK) has entered into a collaboration with Kyowa Hakko Kirin to commercialize daprodustat in Japan.
22 Nov 2018
Life sciences company Cambrex has agreed to acquire Avista Pharma Solutions, a North Carolina-based contract development, manufacturing, and testing organization, for about $252m.
16 Nov 2018
Nexus Pharmaceuticals has announced the immediate availability of Arsenic Trioxide Injection in 10mg per 10mL vial in the US.
14 Nov 2018
AstraZeneca has agreed to offload the US rights of its respiratory drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) in a cash-cum-stock deal worth $1.5bn.
12 Nov 2018
Ferring Pharmaceuticals has announced the US launch of NOCDURNA (desmopressin acetate), a sublingual tablet indicated for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken more than two times per night to void.
07 Nov 2018
AstraZeneca has agreed to offload its rights to asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Covis Pharma for $350m.